JP2022536929A5 - - Google Patents
Info
- Publication number
- JP2022536929A5 JP2022536929A5 JP2021574188A JP2021574188A JP2022536929A5 JP 2022536929 A5 JP2022536929 A5 JP 2022536929A5 JP 2021574188 A JP2021574188 A JP 2021574188A JP 2021574188 A JP2021574188 A JP 2021574188A JP 2022536929 A5 JP2022536929 A5 JP 2022536929A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- use according
- transgene
- adenovirus vector
- oncolytic adenovirus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025101398A JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962861339P | 2019-06-14 | 2019-06-14 | |
| US62/861,339 | 2019-06-14 | ||
| US202062988422P | 2020-03-12 | 2020-03-12 | |
| US62/988,422 | 2020-03-12 | ||
| PCT/FI2020/050422 WO2020249873A1 (en) | 2019-06-14 | 2020-06-12 | Oncolytic adenovirus and checkpoint inhibitor combination therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101398A Division JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022536929A JP2022536929A (ja) | 2022-08-22 |
| JP2022536929A5 true JP2022536929A5 (cg-RX-API-DMAC7.html) | 2023-06-20 |
Family
ID=71670283
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574188A Pending JP2022536929A (ja) | 2019-06-14 | 2020-06-12 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
| JP2025101398A Pending JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025101398A Pending JP2025138703A (ja) | 2019-06-14 | 2025-06-17 | 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220251604A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3983004A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022536929A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220024495A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113924117A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020292610A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021025031A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3138834A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111820PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020249873A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022170919A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京惟亚德生物医药有限公司 | 一种重组溶瘤腺病毒及其应用 |
| CA3233797A1 (en) | 2021-10-04 | 2023-04-13 | Tatiana KUDLING | An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide |
| KR20250158053A (ko) * | 2023-03-01 | 2025-11-05 | 틸트 바이오세러퓨틱스 오이 | 종양용해성 아데노바이러스 벡터의 새로운 투여 요법 |
| CN121335710A (zh) * | 2023-04-07 | 2026-01-13 | 上海复诺健生物科技有限公司 | 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症 |
| CN120835927A (zh) * | 2023-09-28 | 2025-10-24 | 复旦大学附属华山医院 | 用于治疗胶质瘤的组合物 |
| CN117205304A (zh) * | 2023-10-18 | 2023-12-12 | 中国人民解放军海军军医大学第三附属医院 | 维生素c和il-2在制备免疫检查点抑制剂增敏药物中的应用 |
| WO2025159067A1 (ja) * | 2024-01-22 | 2025-07-31 | 国立大学法人 鹿児島大学 | 腫瘍溶解性ウイルス及びそれを用いたがん治療 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| EP3461491B1 (en) * | 2013-04-18 | 2024-11-13 | TILT Biotherapeutics Oy | Enhanced adoptive cell therapy |
-
2020
- 2020-06-12 KR KR1020227000995A patent/KR20220024495A/ko active Pending
- 2020-06-12 JP JP2021574188A patent/JP2022536929A/ja active Pending
- 2020-06-12 CA CA3138834A patent/CA3138834A1/en active Pending
- 2020-06-12 EP EP20742793.1A patent/EP3983004A1/en active Pending
- 2020-06-12 AU AU2020292610A patent/AU2020292610A1/en active Pending
- 2020-06-12 SG SG11202111820PA patent/SG11202111820PA/en unknown
- 2020-06-12 BR BR112021025031A patent/BR112021025031A2/pt unknown
- 2020-06-12 CN CN202080039001.0A patent/CN113924117A/zh active Pending
- 2020-06-12 WO PCT/FI2020/050422 patent/WO2020249873A1/en not_active Ceased
- 2020-06-12 US US17/618,932 patent/US20220251604A1/en active Pending
-
2025
- 2025-06-17 JP JP2025101398A patent/JP2025138703A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| O'Bryan et al. | Oncolytic virotherapy for breast cancer treatment | |
| US11155622B2 (en) | Virus encoding an anti-TCR-complex antibody or fragment | |
| Howells et al. | Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer | |
| JP2025100670A5 (cg-RX-API-DMAC7.html) | ||
| CN105307671B (zh) | 增强过继细胞疗法 | |
| Dong et al. | Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages | |
| JP2020521471A (ja) | 導入遺伝子を保持する組換えアデノウイルス | |
| US11690913B2 (en) | Combining adenovirus and checkpoint inhibitors for treating cancer | |
| JP2021533789A5 (cg-RX-API-DMAC7.html) | ||
| JP2018509914A (ja) | 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用 | |
| JP2020504767A (ja) | 武装した複製可能な腫瘍溶解性アデノウイルス | |
| Huang et al. | Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses | |
| JP2024510712A (ja) | Il-15をコードするアデノウイルス | |
| WO2013123861A1 (zh) | 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途 | |
| Corti et al. | Novel immune targets for the treatment of triple-negative breast cancer | |
| Sultan et al. | Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment | |
| Li et al. | Oncolytic viruses in cancer immunotherapy | |
| SK282235B6 (sk) | Lieková kombinácia na transfekciu a expresiu exogénov in vivo alebo ex vivo | |
| JP7381604B2 (ja) | 癌を治療するための多価pd-l1結合化合物 | |
| Zhu et al. | Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors | |
| Mirbahari et al. | Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade | |
| JP2022502066A (ja) | 癌治療のための修飾b5r遺伝子を有する腫瘍溶解性ワクシニアウイルス | |
| Wang et al. | Novel combination oncolytic adenoviral gene therapy armed with Dm-dNK and CD40L for breast cancer | |
| CA3149918A1 (en) | Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients | |
| JP7699122B2 (ja) | 複製促進腫瘍溶解性アデノウイルス |